Mesenchymal Stem Cell-Derived Exosomes Promote Recovery of The Facial Nerve Injury through Regulating Macrophage M1 and M2 Polarization by Targeting the P38 MAPK/NF-Κb Pathway

Aging Dis. 2024 Apr 1;15(2):851-868. doi: 10.14336/AD.2023.0719-1.

Abstract

Facial nerve (FN) injury seriously affects human social viability and causes a heavy economic and social burden. Although mesenchymal stem cell-derived exosomes (MSC-Exos) promise therapeutic benefits for injury repair, there has been no evaluation of the impact of MSC-Exos administration on FN repair. Herein, we explore the function of MSC-Exos in the immunomodulation of macrophages and their effects in repairing FN injury. An ultracentrifugation technique was used to separate exosomes from the MSC supernatant. Administrating MSC-Exos to SD rats via local injection after FN injury promoted axon regeneration and myelination and alleviated local and systemic inflammation. MSC-Exos facilitated M2 polarization and reduced the M1-M2 polarization ratio. miRNA sequencing of MSC-Exos and previous literature showed that the MAPK/NF-κb pathway was a downstream target of macrophage polarization. We confirmed this hypothesis both in vivo and in vitro. Our findings show that MSC-Exos are a potential candidate for treating FN injury because they may have superior benefits for FN injury recovery and can decrease inflammation by controlling the heterogeneity of macrophages, which is regulated by the p38 MAPK/NF-κb pathway.

MeSH terms

  • Animals
  • Axons
  • Exosomes* / metabolism
  • Facial Nerve Injuries* / therapy
  • Humans
  • Inflammation / metabolism
  • Macrophages / metabolism
  • Mesenchymal Stem Cells* / metabolism
  • NF-kappa B / metabolism
  • Nerve Regeneration
  • Rats
  • Rats, Sprague-Dawley

Substances

  • NF-kappa B

Grants and funding

This project was supported by the Natural Science Foundation of Beijing Municipality, China (Grant No. 7222128), the National Key Research and Development Program of China (Grant No. 2020YFC2005200/ 2020YFC2005203) and the National High Level Hospital Clinical Research Funding (Grant No. 2022-PUMCH-095).